Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2023.13681

OL-25-3-13681

Articles

Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes

Kalitin

Nikolay

1 Dudina

Galina

2 Kostritsa

Natalia

3 Sivirinova

Anastasiya

3 Karamysheva

Aida

1Laboratory of Tumor Cell Genetics, N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia 2Department of Oncohematology, A.S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia 3Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia

Correspondence to: Dr Nikolay Kalitin, Laboratory of Tumor Cell Genetics, N.N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Shosse, 115478 Moscow, Russia, E-mail: f.oskolov@mail.ru

03 2023

26 01 2023

25 3

31082022 30122022

2023

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Vascular endothelial growth factors (VEGFs) are angiogenic factors playing a key role in tumor development. VEGFs are produced by different normal and tumor cells, including platelets, lymphocytes and mononuclear cells of peripheral blood. VEGF (VEGF-A, VEGF-C and VEGF-D) and VEGFR (VEGFR1, VEGFR2 and VEGFR3) gene expression was studied in patients with myelodysplastic syndrome (MDS) to evaluate the possible prognostic role of the expression of these genes. Gene expression levels were determined using peripheral blood samples of 51 patients with MDS and 15 healthy volunteers by quantitative PCR. Expression of all VEGF and VEGFR genes was elevated in patients with MDS compared with healthy volunteers. No association of VEGF-A expression with the hemoglobin content in peripheral blood was found. The analyses of gene expression in patients with MDS stratified by risk groups according to the International Prognostic Scoring System showed progressive augmentation of VEGF-A gene expression from low to high-risk groups and VEGFR1 and VEGFR2 expression from intermediate-1 to high-risk groups. The statistically significant difference in survival time of patients with high and low levels of VEGFR1 expression was revealed. VEGF-A/VEGFR1 expression may be important for risk evaluation of patients with MDS.

myelodysplastic syndrome VEGF-A VEGFR1 gene expression risk factor

Funding: No funding was received.

Introduction

Myelodysplastic syndromes (MDSs) are a heterogeneous group of blood disorders characterized by peripheral blood cytopenia due to ineffective hematopoiesis, dysplasia in ≥1 hematopoietic cell lineages and increased risk of transformation to acute myeloid leukemia (AML). MDSs are hypothesized to be clonal stem cell disorders arising from accumulation of multiple gene abnormalities, such as somatic point mutations, copy-number alterations and chromosomal aberrations (1). Genomic and chromosomal instability and variable molecular mechanisms contribute to pathogenesis and prognosis of MDS (2).

Accumulation of bone marrow (BM) blasts is a key feature and one of the main risk criterion and prognostic factors in patients with MDS (3). However, the majority of patients with MDS die from causes intrinsic to the disease, such as infection, pneumonia, sepsis and bleeding, which are not associated with leukemic transformation (4). This is particularly relevant to patients with lower risk MDS, which is defined as low or intermediate-1-risk according to the International Prognostic Scoring System (IPSS) (5).

VEGFs and their receptors, VEGFRs, are involved in regulation of proliferation, migration, invasion and differentiation of normal and cancer cells (6–9). VEGFs exert their effects by binding to receptors of the VEGFR family that consists of tyrosine kinase receptors, VEGFR1, VEGFR2 and VEGFR3 (10). The role of VEGF-A/VEGFR1 and VEGF-A/VEGFR2 signaling pathways has been evaluated in certain hematological malignancies, such as multiple myeloma, lymphoma and myeloproliferative neoplasms (11–13). However, a potential role of VEGF-A-dependent signaling in MDS pathogenesis has been poorly studied and the results are contradictory. Studies have demonstrated that BM blasts express VEGF-A and modulate VEGF-A-dependent autocrine loop signaling in MDS (14,15). However, Aguayo et al (16) found no prognostic significance of plasma VEGF-A levels in patients with MDS but suggested that VEGF-A plays a role as a prognostic factor in patients with AML. Verstovsek et al (17) showed that increased VEGF-A expression in BM specimens is inversely associated with survival time in patients with MDS or AML, whereas VEGFR1 and VEGFR2 expression levels have no prognostic impact.

To the best of our knowledge, there is no published data on the role of VEGF-C, VEGF-D ligands and VEGFR3 in MDS pathogenesis. However, a previous study revealed that activation of the VEGF-C/VEGFR3 pathway promotes cancer cell mobility to induce metastasis and an increase in VEGF-C and/or VEGFR3 expression may be associated with a shorter survival in numerous types of malignancy (18). The aim of the present study was to evaluate VEGF and VEGFRs expression as putative prognostic markers for MDS.

Patients and methods <sec> <title>Patients and controls

The study group consisted of 51 patients with verified MDS (31 female and 20 male) with a median age of 69.8 years (range, 59–77 years) who were diagnosed between January 1, 2011 and August 31, 2018 and treated at A.S. Loginov Moscow Clinical Scientific Center (Moscow, Russia). The diagnosis of MDS was based on cytological examination of peripheral blood cells. The patients were followed-up from MDS diagnosis until May 31, 2019. The transformation to AML or the death of patients was considered, if they occurred during the follow-up period. The control group consisted of 15 volunteers (8 females and 7 male) free of neoplasms or any other abnormality. The median age and range were 65.3 and 61–68 years, respectively. Clinical and hematological variables (hemoglobin content and platelet and leukocyte count) in the control group were within normal ranges.

Laboratory procedures

Hemoglobin concentration, as well as platelet and leukocyte counts were measured using the automated hematology analyzer ADVIA 2120i according to the manufacturer's recommendations (Siemens Healthineers AG).

Inclusion and exclusion criteria

Inclusion criteria were de novo female and male patients with MDS aged ≥18 years old or patients with MDS who only received prior supportive care (such as red blood cell and/or platelet transfusions for severe anemia and severe thrombocytopenia improvement). Patients treated with erythropoiesis-stimulating agents (in patients with chromosome 5q deletion) were also included. Patients with BM blast cells=5% were excluded. Patients previously treated with hypomethylating agents and/or who received immunosuppressive therapy were excluded. Patients with the hypoplastic variant of MDS as well as patients that refused to participate were not included.

The patient risk stratification according to the 2017 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue (19) and IPSS (20), as well as other patient characteristics are presented in Table I. Karyotype was classified using the International System for Human Cytogenetic Nomenclature (20,21).

Mononuclear cell preparation and cDNA synthesis

The peripheral blood specimens (5–10 ml) were separated using a Ficoll^® density gradient (PanEko) and the obtained mononuclear cell fraction was used for further study. Total RNA was isolated by TRI Reagent^® (Molecular Research Center). All procedures were as previously described (22). Briefly, cDNA synthesis reaction mixture contained 1 µg purified total RNA, 1 µl random 6 primers (Syntol), 2.5 mM dNTP mixture (Thermo Fisher Scientific, Inc.), 0.4 units RNase inhibitor (Thermo Fisher Scientific, Inc.) and 2 units M-MuLVplus reverse transcriptase (Thermo Fisher Scientific, Inc.). The mixture volume was 25 µl. The synthesis was performed in Terzic’ thermocycler (DNA technology, Russia) at 42°С for 50 min with pre-incubating for 10 min at 25°С. The reaction was stopped by heating at 70°С for 10 min.

Quantitative PCR (qPCR)

The amplification of cDNA was performed in a Bio-Rad CFX (Bio-Rad Laboratories, Inc.) detection system using EvaGreen^® dye (Biotium) and qPCR master mix (Syntol) according to the manufacture's protocol. PCR conditions for all genes were 95°С for 5 min followed by 39 cycles of 95°С for 20 sec, 59°С for 25 sec and 72°С for 20 sec. Each sample was measured in triplicate. For data standardization, the 60S subunit of the RPL27 gene was used. The relative expression was determined according to the 2^−∆∆Cq equation [∆C_q=C_q (RPL27)-C_q (test gene), where Cq is the threshold cycle of the gene in the exponential phase of the amplification curve] (23). The following primers were used: VEGF-A forward, 5′-AGGGCAGAATCATCACGAAGT-3′ and reverse, 5′-AGGGCTTCGATTGGATGGCA-3′; VEGF-C forward, 5′-GAGGAGCAGTTACGGTCTGTG-3′ and reverse, 5′-tcctttccttagctgacacttgt-3′; VEGF-D forward, 5′-TCCCATCGGTCCACTAGGTTT-3′ and reverse, 5′-AGGGCTGCACTGAGTTCTTTG-3′; VEGFR1 forward, 5′-TTTGCCTGAAATGGTGAGTAAGG-3′ and reverse, 5′-TGGTTTGCTTGAGCTGTGTTC-3′; VEGFR2 forward, 5′-GGCCCAATAATCAGAGTGGCA-3′ and reverse, 5′-CCAGTGTCATTTCCGATCACTTT-3′; VEGFR3 forward, 5′-TGCACGAGGTACATGCCAAC-3′ and reverse, 5′-GCTGCTCAAAGTCTCTCACGAA-3′ and RPL27 forward, 5′-ACCGCTACCCCCGCAAAGTG-3′ and reverse, 5′-CCCGTCGGGCCTTGCGTTTA-3′.

Statistical analysis

All qPCR experiments were performed in triplicate. Data are presented as the mean ± SEM. Correlation was analyzed using Pearson's rank test. Overall survival was estimated by Kaplan-Meier method with log-rank test. To assess diagnostic value of VEGF and VEGFRs gene expression as candidate biomarkers was performed receiver operating characteristic (ROC) analysis. Area under ROC curve (AUC) was used to compare the discriminatory performance of putative markers to determine their utility as a novel diagnostic test. Statistical significance was analyzed using an unpaired two-tailed Student's t test. P<0.05 was considered to indicate a statistically significant difference. All statistical calculations were performed using GraphPad Prism for Windows program, Version 5.00 (Trial), 2007 (Dotmatics).

Results <sec> <title>VEGF and VEGFR expression is elevated in patients with MDS

VEGF (VEGF-A, VEGF-C and VEGF-D) and VEGFR (VEGFR1, VEGFR2 and VEGFR3) gene expression levels were studied in the peripheral blood samples of 51 patients with MDS and 15 healthy donors. Gene expression varied considerably in patients with MDS compared with healthy donors (Fig. 1A). Although no statistical difference between patients with MDS and controls in VEGFR1 and VEGFR3 expression was found, relative VEGFR1 expression was 0.4-20.0×10⁻³ in patients with MDS and from 1.5×10⁻³ to 4.2×10⁻³ in control group (mean, 2.71±0.46×10⁻³ vs. 2.82±0.19) ×10⁻³. Similarly, VEGFR3 relative expression varied from 0.1-8.0×10⁻³ in patients with MDS and from 0 to 3.4×10⁻³ in controls (mean values: (1.78±0.24) ×10⁻³ vs. 1.02±0.30×10⁻³. VEGF-A and VEGF-C expression were higher in patients with MDS than in controls. The mean values of relative VEGFA expression in patients with MDS and in control group were (19.73±2.84) ×10⁻³ and 11.07±0.99×10⁻³. The mean values of relative VEGF-C expression in MDS patients and control group were (22.50±3.88) ×10⁻³ and 9.23±1.69×10⁻³. VEGFR2 expression levels were low in the group of healthy volunteers (mean value 0.08±0.04) and upregulated in patients with MDS (mean value 0.82±1.39), indicating that VEGFR2-dependent signaling was stimulated in patients with MDS. VEGF-D expression was absent in control group and varied from 0 to 1.4×10⁻³ in patients with MDS.

VEGF-A is activated under hypoxic conditions (24). To evaluate the association between VEGF-A expression and hypoxia, levels of VEGF-A expression and hemoglobin content in the peripheral blood samples of patients with MDS was compared. No correlation was found between these two variables (Fig. 1B). Moreover, the mean value of hemoglobin was almost the same in patients with MDS with different levels of VEGF-A expression (above and below the mean level of 19.62×10⁻³ of relative VEGF-A gene expression; Fig. 1C). Thus, VEGF-A expression was not dependent on the content of hemoglobin in peripheral blood of patients with MDS.

To determine if there was an association between clinical characteristics of patients with MDS and gene expression, levels of hemoglobin, platelets and leukocytes were compared with VEGF and VEGFR gene expression levels. Significant associations were found between levels of platelets and the expression levels of VEGF-C and VEGF-D (Fig. 1D and E).

VEGF and VEGFR expression in patients with MDS with different risk of disease development

All patients with MDS were stratified in the present study, according to the IPSS. Patients were assigned to low (15 patients), intermediate-1 (12 patients), intermediate-2 (9 patients) and high (15 patients) risk groups and the survival time and gene expression in these groups were compared. No statistical difference in survival time between any of these risk groups was found. Nevertheless, the median survival time diminished from the intermediate-1 (51 months) and intermediate-2 (49 months) risk groups to the high-risk group (23 months). The median survival time in the low-risk group was not reached (Fig. 2A).

VEGF-A expression was progressively elevated from the low to the high-risk groups (Fig. 2). A statistically significant difference was found for VEGF-A expression between the low and intermediate-2 risk groups, as well as between the low and high-risk groups. No statistically significant difference between risk groups in VEGF-C, VEGF-D, VEGFR1 and VEGFR2 expression was found. Expression of VEGFR1 and VEGFR2 genes was notably elevated from the intermediate-1 to the high-risk group. VEGF-C and VEGF-D expression was notably higher in the low-risk group of patients compared with the other groups. VEGFR3 expression was lowest in the high risk group. The only statistically significant difference in gene expression was found between the intermediate-2 and high risk groups for VEGFR3.

VEGF and VEGFR expression in patients with MDS with different levels of BM blasts

A key prognostic factor characterizing patients with MDS is the percentage of BM blast cells. BM blast cells <5% is usually associated with good prognosis (20). In the present study, all patients from low and intermediate-1 risk groups had BM blast levels <5% and patients from intermediate-2 and high-risk groups had BM blast levels >5%. The survival time and gene expression levels of MDS patients with BM blast levels <5% (27 patients) and >5% (24 patients) were compared. No significant difference in survival time between these patients was found, although the median survival times were different (51 vs. 28 months for <5% and >5% BM blast levels, respectively; Fig. 3A).

Although there was no statistically significant difference, the mean VEGF-A, VEGFR1 and VEGFR2 expression levels were elevated in patients with MDS with >5% BM blast levels (Fig. 3B and C). VEGF-C, VEGF-D and VEGFR3 expression was decreased in the group of patients with MDS with BM blast levels >5%.

The prognostic evaluation of potential clinical outcomes in MDS patients with BM blast levels <5% is complicated. Some of these patients die within a few months of developing AML transformation or other complications of bone marrow failure, while others can survive for a long time (25). Survival time of patients with BM blast levels <5% (group 1, 9 patients) did not differ from that of patients with BM blast levels >5% (17 vs. 14 months, respectively), while patients of a group 2 with BM blast levels <5% had an improved survival (group 2, 18 patients; Fig. 3A). VEGF and VEGFRs gene expression levels in groups 1 and 2 were compared (Fig. 3D and E) and VEGF-A, VEGF-C, VEGFR1 and VEGFR2 expression in these groups was very similar to that in patients with MDS with BM blast levels >5 and <5% (Fig. 3B and C).

Survival of MDS patients with different VEGF-A and VEGFR1 expression levels

As both VEGF-A and VEGFR1 gene expression levels were elevated in patients with MDS with a worse prognosis, the survival of patients was compared. No statistically significant difference was found between patients with MDS with high and low levels of VEGF-A expression, although the median survival times in patients with VEGF-A expression levels above (18 patients) and below (33 patients) the mean value (1.96х10⁻³) were different (23 and 43 months, respectively; Fig. 4A). Patients with MDS with VEGFR1 expression levels exceeding the mean relative VEGFR1 gene expression (2.69х10⁻³; 15 patients) had statistically worse survival (log-rank test; Fig. 4B) with a median survival time of 17 months compared with 48 months for the group with low levels of VEGFR1 expression (36 patients).

To evaluate the diagnostic value of VEGF-A and VEGFR1 gene expression levels as candidate biomarkers of MDS, receiver operating characteristic (ROC) curve analysis was applied. Area under the curve (AUC) was 0.57 for the VEGF-A gene, but the result was not statistically significant (Fig. 5A). However, VEGFR1 expression levels discriminated between patients with MDS and the healthy controls (AUC=0.684), suggesting its potential diagnostic value (Fig. 5B).

Discussion

Due to the heterogeneity of MDSs at morphological, clinical and molecular levels, the accurate diagnosis of these diseases has certain problems (subjectivity of morphological assessment of bone marrow aspirate and biopsy, as well as heterogeneity of cytogenetic alterations) and the expected clinical outcome for patients with MDS is different. Whereas some patients transform to AML or die from complications of BM transplant failure within a few months, other patients with MDS survive for years without major hematological problems (26). A precise diagnosis is important for the prediction of patient survival and risk of AML transformation and selection of appropriate therapy.

Several classification systems have been presented to evaluate MDS diagnosis, the most commonly used being the French-American-British (FAB) (19) and IPSS (20) classification. In the present study, patients with MDS were stratified according to IPSS scoring. The diagnosis of MDS is often based on morphological characteristics, and due to the subjectivity of this evaluation, discrepancy in MDS diagnoses exists. Naqvi et al (27) analyzed discordance between the diagnosis of 915 patients with MDS referred according to FAB or IPSS and final diagnosis, and found that 12% of diagnoses (109/915 patients) were reclassified. Most of the reclassified patients (67% classified according to FAB and 77% classified by IPSS) had higher risk disease. According to the WHO 2017 classification, a correct diagnosis of MDS requires the integration of not only morphological but also clinical, cytogenetic and, potentially, molecular biology parameters, thus providing an improved classification of MDS diagnosis (19). Diagnosis is more obvious in patients with excess BM blasts: Increased blast percentages (>5–10%) indicate an increase in risk of leukemic transformation and of death (28). The patients with early low-risk disease need additional diagnostic tools, including cytogenetic evaluation, flow cytometry and DNA sequencing, to define the diagnosis and predict outcomes (29). New biological markers may also be helpful to stratify patients with MDS.

VEGF and one of its receptors, VEGFR2, are prognostic factors for a number of solid tumors such as primary (30) and non-small cell lung cancer (31), neuroblastoma (32) and bladder (33), colon (34) and breast cancer (35). To the best of our knowledge, however, the data on VEGF-dependent signaling and its role in MDS development are scarce. A study showed an increase in BM microvessel density (MVD) in refractory anemia with excess blasts in transformation (RAEB-T), chronic myelomonocytic leukemia and AML compared with patients with RA, RA with ring sideroblasts and RAEB (36). VEGF expression in MDS specimens is especially high in RAEB ± T and AML samples (14). VEGFR1 and, to a lesser extent, VEGFR2 are expressed in patients with MDS and exhibit autocrine cytokine interaction (14,17).

Based on expression data of VEGF and its receptors in MDS, it was suggested that VEGF-dependent signaling could be a potential therapeutic target (7,17). A number of agents interfering with VEGF signaling, such as bevacizumab (37), SU5416 (38), AG-013736 (39), Vatalanib (40), Aflibercept/NSC 724770 (41), have been tested in patients with MDS, but yielded no or small clinical responses and clinical applicability is limited by toxicity and side effects.

The results of investigations on the VEGF prognostic impact in patients with MDS are also not encouraging. The prognostic significance of VEGF plasma levels in patients with AML and MDS has been studied (16): VEGF plasma levels are associated with a shorter survival in patients with AML, but not MDS. By contrast, elevated BM cellular VEGF levels are significantly associated with shorter survival in patients with MDS (17). Cheng et al (42) studied the potential prognostic value of VEGF-A, VEGF-C, angiopoietin-1 (Ang-1), Ang-2 and receptor Tie-2 expression in the BM of patients with MDS. Ang-1, but not Ang-2, VEGFs or Tie-2, was shown to be an independent poor prognostic factor for patients with MDS.

Despite elevated BM MVD in patients with MDS, the treatment with anti-VEGF or its receptor agents does not produce any appreciable therapeutic effects. The attempts to evaluate the potential of VEGF or its receptors to be prognostic factors for patients with MDS also were not fruitful.

In the present study, relative mRNA expression levels of VEGF (VEGF-A, VEGF-C and VEGF-D) and VEGF receptors (VEGFR1, VEGFR2 and VEGFR3) in peripheral blood samples of patients with MDS were augmented compared with healthy control samples, suggesting that VEGF-dependent signaling was activated in patients with MDS. Although VEGF-A is activated under hypoxia, no association between VEGF-A expression and hemoglobin content in peripheral blood samples was found. The comparison of VEGF and VEGFR gene expression levels in patients with MDS subdivided according to IPSS risk revealed increased VEGF-A, VEGFR1 and VEGFR2 expression in higher risk groups, with the most significant difference for VEGFR1 expression.

A key predictor of MDS development is levels of BM blast cells in patients (28) Patients with MDS with BM blast levels <5% included all patients from the IPSS system low and intermediate-1-risk groups; patients with MDS with BM blast levels >5% comprised the intermediate-2 and high-risk groups.

The difference in overall survival of patients stratified by BM blast levels (patients with >5% vs. patients with <5% blasts) was not statistically significant, but median survival time varied considerably (51 vs. 28 months, respectively). VEGF-A, VEGFR1 and VEGFR2 gene expression was upregulated in patients with MDS with BM blast levels >5% compared with patients with BM blast levels <5%. By contrast, VEGF-C, VEGF-D and VEGFR3 gene expression levels were elevated in patients with MDS with BM blast levels <5%. This suggested that VEGF-A/VEGFR1 and VEGFR2 signaling was activated and VEGF-C and VEGF-D/VEGFR3 signaling was suppressed in patients with BM blast levels >5%.

In the present study, according to the survival curve of patients with MDS with BM blast levels <5%, two groups of patients were discriminated. The survival curve of a subgroup of these patients (group 1) largely coincided with the survival curve of patients with BM blast levels >5%, while the survival curve of patients with BM blast levels <5% (group 2) differed. The comparison of VEGF and VEGFR gene expression levels in groups 1 and 2 revealed similar gene expression, as in groups of patients with BM blast levels >5 and <5%, with the exception of VEGF-D and VEGFR3 genes. As such, the elevation of certain VEGF (VEGF-A) and VEGFR (VEGFR1 and VEGFR2) gene expression levels in patients with MDS with BM blast levels <5% may indicate the intensification of disease.

As the most prominent difference in gene expression levels between groups concerned VEGF-A and VEGFR1, the survival of patients with MDS subdivided by these gene expression levels was analyzed. A significant difference in survival was found for subgroups by VEGFR1 expression. The survival rate of patients with MDS with VEGFR1 expression below the mean, but not the median level of expression, was higher than in patients with higher levels of this gene expression. The difference in survival of patients subdivided by VEGF-A expression was not significant, but the median survival times in groups with higher VEGF-A expression differed significantly from those in groups with lower expression (23 vs. 43 months in groups subdivided by the mean expression and 17 vs. 48 months in groups subdivided by the median level of expression).

VEGF-A exerts its function through binding with its two specific receptors-VEGFR1 and VEGFR2, where VEGFR2 is the primary mediator of such VEGF-A biological functions as embryogenesis and hematopoiesis (43,44). According to the present study, expression of VEGFR2, the known negative prognostic factor for many solid tumors, (45–47) is not important in MDS. It was hypothesized that VEGF-A-dependent signaling may be preferentially realized through another receptor for VEGF-A, VEGFR1, as VEGFR1 expression is higher in the peripheral blood samples of patients with MDS compared with VEGFR2 expression. Previous data on VEGF and VEGFR expression levels in BM samples of patients with MDS have shown increased expression of VEGFR1, but not VEGFR2 (48). Only VEGFR1 expression in the present study had prognostic impact for patients with MDS. The elevated VEGF-A/VEGFR1 expression in patients with MDS with BM blast levels >5% and patients with BM blast levels <5% with worse survival (group 1) indicated that the progression of the disease was accompanied by VEGF-A/VEGFR1 activation. ROC analysis showed that VEGFR1 expression rather than VEGF-A expression could serve as a potential prognostic marker in MDS with low and intermediate-1 risk.

Acknowledgements

Not applicable.

Availability of data and materials

The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

NKa, GD, NKo, AS and AK contributed to study conception and design. Clinical material preparation and data collection were performed by GD. RT-qPCR analysis was performed by NKa, NKo and AS. AK and NKa analyzed gene expression data and wrote the manuscript. GD, NKa, NKo, AS and AK confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved (approval no. 6/2016) by the ethics commission of the A.S. Loginov Moscow Clinical Scientific Center (Moscow, Russia). All patients and volunteers provided written informed consent to participate in the present study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Papaemmanuil

Gerstung

Malcovati

Tauro

Gundem

Van Loo

Yoon

Ellis

Wedge

Pellagatti

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Blood1223616362736992013

10.1182/blood-2013-08-518886

24030381

Odenike

Anastasi

Le Beau

Myelodysplastic Syndromes

Clin Lab Med317637842011

10.1016/j.cll.2011.08.005

22118747

Foucar

Myelodysplastic/myeloproliferative neoplasms

Am J Clin Pathol1322812892009

10.1309/AJCPJ71PTVIKGEVT

19605822

Dayyani

Conley

Strom

Stevenson

Cortes

Borthakur

Faderl

O'Brien

Pierce

Kantarjian

Garcia-Manero

Cause of death in patients with lower-risk myelodysplastic syndrome

Cancer116217421792010

20162709

Garcia-Manero

Myelodysplastic syndromes: 2014 Update on diagnosis, risk-stratification, and management

Am J Hematol89971082014

10.1002/ajh.23642

24464505

Price

Miralem

Jiang

Steinberg

Avraham

Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells

Cell Growth Differ121291352001

11306513

Podar

Anderson

The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications

Blood105138313952005

10.1182/blood-2004-07-2909

15471951

Lee

Seng

Sekine

Hinton

Avraham

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1

PLoS Med4e1862007

10.1371/journal.pmed.0040186

17550303

Adams

Alitalo

Molecular regulation of angiogenesis and lymphangiogenesis

Nat Rev Mol Cell Biol84644782007

10.1038/nrm2183

17522591

Veikkola

Karkkainen

Claesson-Welsh

Alitalo

Regulation of angiogenesis via vascular endothelial growth factor receptors

Cancer Res602032122000

10667560

Vincent

Jin

Karajannis

Shido

Hooper

Rashbaum

Pytowski

Hicklin

Zhu

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells

Cancer Res65318531922005

10.1158/0008-5472.CAN-04-3598

15833849

Wang

Teruya-Feldstein

Zhu

Hicklin

Moore

Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo

Blood104289329022004

10.1182/blood-2004-01-0226

15238424

Boiocchi

Vener

Savi

Bonoldi

Moro

Fracchiolla

Iurlo

Deliliers

Coggi

Bosari

Gianelli

Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosomenegative myeloproliferative neoplasms

J Clin Pathol642262312011

10.1136/jcp.2010.083386

21217153

Bellamy

Richter

Sirjani

Roxas

Glinsmann-Gibson

Frutiger

Grogan

List

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

Blood97142714342001

10.1182/blood.V97.5.1427

11222390

Wimazal

Krauth

Vales

Böhm

Agis

Sonneck

Aichberger

Mayerhofer

Simonitsch-Klupp

Müllauer

Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: Correlation between VEGF expression and the FAB category

Leuk Lymphoma474514602006

10.1080/10428190500353083

16396768

Aguayo

Kantarjian

Estey

Giles

Verstovsek

Manshouri

Gidel

O'Brien

Keating

Albitar

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

Cancer95192319302002

10.1002/cncr.10900

12404286

Verstovsek

Estey

Manshouri

Giles

Cortes

Beran

Rogers

Keating

Kantarjian

Albitar

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

Br J Haematol1181511562002

10.1046/j.1365-2141.2002.03551.x

12100142

Yen

Chen

Chuang

Hong

Kuo

Chen

Hung

Kuo

The role of the VEGF-C/VEGFR-3 axis in cancer progression

Br J Cancer965415452007

10.1038/sj.bjc.6603487

17164762

Swerdlow

Campo

Harris

Jaffe

Pileri

Stein

Thiele

WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues

Revised 4th edition

IARC

Lyon

2017

Greenberg

Tuechler

Schanz

Sanz

Garcia-Manero

Solé

Bennett

Bowen

Fenaux

Dreyfus

Revised international prognostic scoring system for myelodysplastic syndromes

Blood120245424652012

10.1182/blood-2012-03-420489

22740453

Shaffer

Slovak

Campbell

ISCN 2009: An international system for human cytogenetic nomenclature (2009)

Basel, Switzerland

S. Karger

2009

Kalitin

Buravtsova

Transcription factor RARa expression correlates with VEGFR3-dependent signaling system components expression in multiple myeloma

Klinicheskaya Onkogematologiya831362015(In Russian)

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Dor

Porat

Keshet

Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis

Am J Physiol Cell Physiol280C1367C13742001

10.1152/ajpcell.2001.280.6.C1367

11350731

Greenberg

Cox

LeBeau

Fenaux

Morel

Sanz

Vallespi

Hamblin

Oscier

International scoring system for evaluating prognosis in myelodysplastic syndromes

Blood89207920881997

10.1182/blood.V89.6.2079

9058730

Wimazal

Sperr

Kundi

Meidlinger

Fonatsch

Jordan

Thalhammer-Scherrer

Schwarzinger

Geissler

Lechner

Valent

Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes

Leuk Res252872942001

10.1016/S0145-2126(00)00140-5

11248325

Naqvi

Jabbour

Bueso-Ramos

Pierce

Borthakur

Estrov

Ravandi

Faderl

Kantarjian

Garcia-Manero

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

Blood118469046932011

10.1182/blood-2011-03-342642

21868570

Mufti

Bennett

Goasguen

Bain

Baumann

Brunning

Cazzola

Fenaux

Germing

Hellström-Lindberg

Diagnosis and classification of myelodysplastic syndrome: International working group on morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

Haematologica93171217172008

10.3324/haematol.13405

18838480

Montalban-Bravo

Garcia-Manero

Myelodysplastic syndromes: 2018 Update on diagnosis, risk-stratification and management

Am J Hematol931291472018

10.1002/ajh.24930

29214694

Ohta

Endo

Tanaka

Shimizu

Oda

Hayashi

Watanabe

Sasaki

Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer

Clin Cancer Res2141114161996

9816315

Fontanini

Bigini

Vignati

Basolo

Mussi

Lucchi

Chine

Angeletti

Harris

Bevilacqua

Microvessel count predicts metastatic disease and survival in non-small cell lung cancer

J Pathol17757631995

10.1002/path.1711770110

7472781

Meitar

Crawford

Rademaker

Cohn

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma

J Clin Oncol144054141996

10.1200/JCO.1996.14.2.405

8636750

O'Brien

Cranston

Fuggle

Bicknell

Harris

Different angiogenic pathways characterize superficial and invasive bladder cancer

Cancer Res555105131995

7530595

Takahashi

Kitadai

Bucana

Cleary

Ellis

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer

Cancer Res55396439681995

7664263

Anan

Morisaki

Katano

Ikubo

Kitsuki

Uchiyama

Kuroki

Tanaka

Torisu

Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer

Surgery1193333391996

10.1016/S0039-6060(96)80120-6

8619189

Pruneri

Bertolini

Soligo

Carboni

Cortelezzi

Ferrucci

Buffa

Lambertenghi-Deliliers

Pezzella

Angiogenesis in myelodysplastic syndromes

Br J Cancer81139814011999

10.1038/sj.bjc.6693515

10604739

Legros

Slama

Karsenti

Vey

Natarajan-Amé

Watel

Richard

Bouabdallah

Mannone

Benchetrit

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

Ann Hematol9139462012

10.1007/s00277-011-1242-z

21553011

Giles

Stopeck

Silverman

Lancet

Cooper

Hannah

Cherrington

O'Farrell

Yuen

Louie

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Blood1027958012003

10.1182/blood-2002-10-3023

12649163

Giles

Bellamy

Estrov

O'Brien

Verstovsek

Ravandi

Beran

Bycott

Pithavala

Steinfeldt

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Leuk Res308018112006

10.1016/j.leukres.2005.10.024

16332390

Gupta

Mulkey

Hasserjian

Sanford

Vij

Hurd

Odenike

Bloomfield

Owzar

Stone

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and leukemia group B study 10105 (alliance)

Invest New Drugs31131113202013

10.1007/s10637-013-9978-z

23700288

Kirschbaum

Frankel

Synold

Zain

Claxton

Tuscano

Newman

Gandara

Lara

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: A California cancer consortium study

Br J Haematol1804454482018

10.1111/bjh.14333

27650362

Cheng

Hou

Jhuang

Lin

Chen

Tang

Chou

Tseng

Yao

Huang

High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes

Br J Cancer1059759822011

10.1038/bjc.2011.340

21878936

Shalaby

Rossant

Yamaguchi

Gertsenstein

Breitman

Schuh

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

Nature37662661995

10.1038/376062a0

7596435

Eichmann

Corbel

Nataf

Vaigot

Bréant

Le Douarin

Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2

Proc Natl Acad Sci USA94514151461997

10.1073/pnas.94.10.5141

9144204

Carrillo de Santa

Arias

Caso Peláez

Muñoz Molina

Sánchez Hernández

Muguruza Trueba

Moreno Balsalobre

Sacristán López

Gómez Pinillos

del Val Toledo Lobo

Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with non-small cell lung cancer

Cancer115170117122009

10.1002/cncr.24193

19197998

Ock

Nam

Bang

Kim

Lee

Han

Kim

Bang

The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer

Am J Cancer Res5337633882015

26807318

Dhakal

Naume

Synnestvedt

Borgen

Kaaresen

Schlichting

Wiedswang

Bassarova

Holm

Giercksky

Nesland

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: Prognostic significance and relationship with markers for aggressiveness

Histopathology613503642012

10.1111/j.1365-2559.2012.04223.x

22690749

Kalitin

Dudina

Semochkin

Karamysheva

Analysis of VEGF-A/VEGFR1/VEGFR2 genes expression analyses in patients with myelodysplastic syndromes

Ther Arch8939442017(In Russian)

10.17116/terarkh201789739-44

28766539

Figure 1.

VEGF and VEGFR expression, the Hb content and Plt count in patients with MDS. (A) Relative VEGF and VEGFRs gene expression in patients with MDS and healthy controls using reverse transcription-quantitative PCR. (B) Distribution of patients with MDS according to VEGF-A expression and Hb content. (C) VEGF-A expression and Hb levels (g/dl) in patients with MDS with VEGF-A expression above or below its median level (13.0×10⁻³). (D) VEGF-C expression and Plt (×10⁹/l) levels in patients with MDS with VEGF-C expression above or below its median level (12.0×10⁻³). (E) VEGF-D expression and Plt (×10⁹/l) levels in patients with MDS with VEGF-D expression above or below its median level (0.05×10⁻³). Data are presented as the mean ± SEM and were analyzed using an unpaired two-tailed Student's t-test. *P<0.05, **P<0.01, ***P<0.001. MDS, myelodysplastic syndrome; Hb, hemoglobin; Plt, platelet.

Figure 2.

Survival and VEGF and VEGFRs expression in different groups of patients with MDS. (A) Overall survival in patients with MDS and low, Int.1, Int.2 and high-risk of disease development. (B) Relative VEGF and VEGFRs expression in MDS patients with low, Int.1, Int.2 and High-risk of disease development. Data are presented as the mean ± SEM and were analyzed using an unpaired two-tailed Student's t test. *P<0.05. Int, intermediate.

Figure 3.

Survival and VEGFs, VEGFR expression in different groups of patients with MDS. (A) Kaplan-Meier survival curves of patients with MDS with differing levels of BM blasts; cut-off value of blasts was 5%. Patients with MDS with BM blast levels <5% were subdivided into groups of patients with a worse (group 1) and improved (group 2) survival rate. Relative (B) VEGF and (C) VEGFR gene expression in groups of patients with MDS with >5 or <5% BM blast levels. Relative (D) VEGF and (E) VEGFR expression in groups 1 and 2 of patients with MDS. Data are presented as mean ± SEM and were analyzed using an unpaired two-tailed Student's t test. *P<0.05. M, median; MDS, myelodysplastic syndrome.

Figure 4.

Kaplan-Meier survival curves of patients with myelodysplastic syndrome with high and low expression levels of (A) VEGF-A (mean, 1.96×10⁻²) and (B) VEGFR1 (mean, 2.69×10⁻³). M, median.

Figure 5.

Receiver operating characteristic curve analysis of (A) VEGF-A and (B) VEGFR1 gene expression levels for predicting diagnostic significance in patients with myelodysplastic syndrome (n=51). AUC, area under the curve.

Table I.

Clinical variables of 51 patients with MDS.

Clinical variable	Value
Median age (range), years	69.80 (59.00–77.00)
Sex, n
Female	31.00
Male	20.00
WHO classification, n
MDS-SLD	8.00
MDS-RS	2.00
MDS-MLD	11.00
MDS-EB^a	22.00
MDS-del(5q)	8.00
IPSS classification, n
Low	15.00
Intermediate-1	12.00
Intermediate-2	9.00
High	15.00
Karyotype^b, n
Good	30.00
Intermediate	2.00
Poor	6.00
n/d	13.00
Mean hemoglobin count ± SEM, g/dl	6.59±1.60
Mean platelets count ± SEM, ×10⁹/l	118.33±60.85
Mean leukocyte count ± SEM, ×10⁹/l	4.67±3.53
Bone marrow blasts, n
>5%	24.00
<5%	27.00
AML progression, n	14.00
Death, n	26.00
Survival time ± SD, months	24.80±22.68

MDS-EB is EB1 + EB2.

Cytogenetic subgroups: Good, normal karyotype. Isolated-Y, del(5q) or del(20q); poor, ≥3 abnormalities or chromosome 7 anomalies; intermediate, other abnormalities; n/d, not determined; MDS-SLD, myelodysplastic syndrome with single-lineage dysplasia; MDS-RS, MDS with ring sideroblasts; MDS-MLD, MDS with multilineage dysplasia; MDS-EB, MDS with excess blasts; MDS-del(5q), MDS with isolated 5q-deletion; IPSS, International Prognosis Scoring System; AML, acute myeloid leukemia.